ROVE-HOTELS
15.12.2020 12:58:15 CET | Business Wire | Press release
Introducing Rove La Mer Beach, a brand-new hotel on the sunny shores of Dubai’s iconic La Mer beachfront, where the surf meets the city. Guided by Dubai Tourism’s vision to offer global travellers customisable experiences suitable for every type of visitor, Rove La Mer Beach gives Rovers (guests) the perfect excuse to soak in the sun, sand and pristine beach waters, explore trendy restaurants, and enjoy an affordable beachside stay. Centrally located, only a 10-minute drive from City Walk and Downtown Dubai.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201215005579/en/
“ Rove La Mer Beach is Rove Hotels’ first beachfront hotel and an exciting step in the brand’s journey. As we add more and more convenient locations to our ever-growing collection of well-connected hotels, we continue to find new ways to engage the modern traveller with a diverse array of enriching experiences. By bringing fun, affordable and fuss-free hospitality to La Mer, Rove aims to redefine people’s expectations of what a beachfront hotel is supposed to be and make them accessible to a wider range of travellers ,” says Paul Bridger of Rove Hotels.
Cool, Comfortable Stays
An ideal escape to the seascape for a cool, comfortable, relaxing stay, Rove La Mer Beach offers choices of two Rover Room types, one with skyline views, the other with sea views, along with interconnecting room options. Each room is fully equipped with all essentials, plus a Juliet balcony to admire breath-taking views of the city and sea.
Dubai’s Eclectic Beachfront, Right at the Doorstep
Featuring a waterpark, cinema, inflatable playgrounds, water-sports, boutique stores, 50+ gourmet restaurants, lounges, outdoor sports facilities, and more, Rove La Mer Beach is located on the beachfront of one of Dubai’s most exciting outdoor destinations, offering plenty of activities for solo adventurers and families.
Relaxed Beachside Experiences
Rove La Mer Beach features a variety of food and beverage options, both indoors and outdoors at the hotel terrace, overlooking the beach. With refreshing bevvies at the Drink Truck, vibrant music, drinks at the Beach Bar, and all-day dining at The Daily – there’s something for everyone.
Special Opening Offer
Book a stay at Rove La Mer Beach through rovehotels.com from $100++ per night, including a sea-view upgrade, late check-out and 30% off food and drinks (until 31st January 2021).
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20201215005579/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom